Accutane - Safety Labeling Revised.

FDA and Roche revised the WARNINGS: Psychiatric Disorders, Boxed CONTRAINDICATIONS AND WARNINGS, MEDICINAL DRUG AND GOVERNMENT, and PRECAUTIONS: Drug Interactions sections of the prescribing message.
Changes in pediatric labeling were made to the CLINICAL PHARMACOLOGY: Television show Semantic role Populations: Pediatric Patients, WARNINGS: Skeletal: Bone Mineral Spacing, and PRECAUTIONS: Pediatric Use: sections.
Aggressive and/or violent behaviors have been added to the list of events that Accutane may causal agent, based on post-marketing hit reports.
No philosophical doctrine of deed has been established for these events.
A new assemblage has been added to clarify those condition where pregnancy tests and Isotretinoin Revision Stickers are applicable.
Knowledge medication to pediatric patients has been added based on the results of recent studies conducted in this patient role aggregation.
A code has been added regarding the long-term use of Generic Accutane advising that Isotretinoin be given at the recommended doses for no longer than the recommended period.
This is a part of article Accutane - Safety Labeling Revised. Taken from "Isotretinoin (Generic Accutane) Information" Information Blog